Skip to main content

letter

. 1996 Mar 16;312(7032):703–705. doi: 10.1136/bmj.312.7032.703b

Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Selegeline may be toxic in presence of increased dopamine concentrations.

P H Yu, C T Lai, A A Boulton

PMCID: PMC2350556 PMID: 8597749

703

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

Lees A. J. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom. BMJ. 1995 Dec 16;311(7020):1602–1607. doi: 10.1136/bmj.311.7020.1602. [DOI] [PMC free article] [PubMed] [Google Scholar]
Singer T. P. The colorful past and bright future of monoamine oxidase research. Prog Brain Res. 1995;106:1–22. doi: 10.1016/s0079-6123(08)61197-8. [DOI] [PubMed] [Google Scholar]
Yu P. H., Davis B. A., Boulton A. A. Aliphatic propargylamines: potent, selective, irreversible monoamine oxidase B inhibitors. J Med Chem. 1992 Oct 2;35(20):3705–3713. doi: 10.1021/jm00098a017. [DOI] [PubMed] [Google Scholar]

ACTIONS

RESOURCES